Tango Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| AccumulatedOther | ||||||
|---|---|---|---|---|---|---|
| Common Stock Outstanding · Additional · Comprehensive · Total | ||||||
| Shares | Amount | Paid-inCapital | Income(Loss) | AccumulatedDeficit | Stockholders’Equity | |
| Balance at December 31, 2022 | 88,179,374 | 88 | 522,605 | (3,705) | (269,512) | 249,476 |
| Issuance of common stock under stock plans | 826,714 | — | 1,941 | — | — | 1,941 |
| Stock based compensation expense | — | — | 19,079 | — | — | 19,079 |
| Common shares and pre-funded stock warrants issued in offerings, net of issuance costs | 13,196,671 | 14 | 79,762 | — | — | 79,776 |
| Return of capital from a stockholder - related party | — | — | 689 | — | — | 689 |
| Other comprehensive income | — | — | — | 3,891 | — | 3,891 |
| Net loss | — | — | — | — | (101,744) | (101,744) |
| Balance at December 31, 2023 | 102,202,759 | $102 | $624,076 | $186 | $(371,256) | $253,108 |
| Issuance of common stock under stock plans | 1,525,384 | 2 | 5,939 | — | — | 5,941 |
| Stock based compensation expense | — | — | 28,897 | — | — | 28,897 |
| Common shares issued in offering, net of issuance costs | 4,001,200 | 4 | 41,719 | — | — | 41,723 |
| Other comprehensive income | — | — | — | 150 | — | 150 |
| Net loss | — | — | — | — | (130,302) | (130,302) |
| Balance at December 31, 2024 | 107,729,343 | $108 | $700,631 | $336 | $(501,558) | $199,517 |
| Issuance of common stock under stock plans | 3,115,187 | 3 | 10,133 | — | — | 10,136 |
| Stock based compensation expense | — | — | 26,430 | — | — | 26,430 |
| Common shares and pre-funded stock warrants issued in offerings, net of issuance costs | 22,755,438 | 23 | 211,779 | — | — | 211,802 |
| Exercise of pre-funded stock warrants | 2,340,486 | 2 | (2) | — | — | — |
| Other comprehensive loss | — | — | — | (112) | — | (112) |
| Net loss | — | — | — | — | (101,594) | (101,594) |
| Balance at December 31, 2025 | 135,940,454 | $136 | $948,971 | $224 | $(603,152) | $346,179 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.